Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation

Trial Profile

Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Delayed graft function
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2018 Status changed from active, no longer recruiting to discontinued.
    • 11 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top